Literature DB >> 15310764

Hypoxia-induced nucleophosmin protects cell death through inhibition of p53.

June Li1, Xiaoling Zhang, Daniel P Sejas, Grover C Bagby, Qishen Pang.   

Abstract

Nucleophosmin (NPM) is a multifunctional protein that is overexpressed in actively proliferating cells and cancer cells. Here we report that this proliferation-promoting protein is strongly induced in response to hypoxia in human normal and cancer cells. Up-regulation of NPM is hypoxia-inducible factor-1 (HIF-1)-dependent. The NPM promoter encodes a functional HIF-1-responsive element that can be activated by hypoxia or forced expression of HIF-1alpha. Suppression of NPM expression by small interfering RNA targeting NPM increases hypoxia-induced apoptosis, whereas overexpression of NPM protects against hypoxic cell death of wild-type but not p53-null cells. Moreover, NPM inhibits hypoxia-induced p53 phosphorylation at Ser-15 and interacts with p53 in hypoxic cells. Thus, this study not only demonstrates hypoxia regulation of a proliferation-promoting protein but also suggests that hypoxia-driven cancer progression may require increased expression of NPM to suppress p53 activation and maintain cell survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310764     DOI: 10.1074/jbc.C400297200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Targeted genes and interacting proteins of hypoxia inducible factor-1.

Authors:  Wei Liu; Shao-Ming Shen; Xu-Yun Zhao; Guo-Qiang Chen
Journal:  Int J Biochem Mol Biol       Date:  2012-05-31

Review 2.  Nucleophosmin and human cancer.

Authors:  Mi Jung Lim; Xin Wei Wang
Journal:  Cancer Detect Prev       Date:  2006-11-17

3.  Over Expression of Nucleophosmin and Nucleolin Contributes to the Suboptimal Activation of a G2/M Checkpoint in Ataxia Telangiectasia Fibroblasts.

Authors:  Narasimharao Nalabothula; Devulapalli Chakravarty; Adam Pierce; France Carrier
Journal:  Mol Cell Pharmacol       Date:  2010

4.  Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.

Authors:  June Li; Daniel P Sejas; Sandeep Burma; David J Chen; Qishen Pang
Journal:  Carcinogenesis       Date:  2007-02-02       Impact factor: 4.944

5.  Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome.

Authors:  Leonard B Maggi; Michael Kuchenruether; David Y A Dadey; Rachel M Schwope; Silvia Grisendi; R Reid Townsend; Pier Paolo Pandolfi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

6.  mTOR transcriptionally and post-transcriptionally regulates Npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.

Authors:  Rafik Boudra; Rosyne Lagrafeuille; Corinne Lours-Calet; Cyrille de Joussineau; Gaëlle Loubeau-Legros; Cédric Chaveroux; Jean-Paul Saru; Silvère Baron; Laurent Morel; Claude Beaudoin
Journal:  Cell Cycle       Date:  2016-05-18       Impact factor: 4.534

Review 7.  Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke.

Authors:  Honglian Shi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

8.  Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment.

Authors:  Shuhong Guo; Minoru Miyake; Ke Jian Liu; Honglian Shi
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

9.  NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice.

Authors:  Wei Du; Yun Zhou; Suzette Pike; Qishen Pang
Journal:  Carcinogenesis       Date:  2009-11-23       Impact factor: 4.944

10.  CSB protein is (a direct target of HIF-1 and) a critical mediator of the hypoxic response.

Authors:  Silvia Filippi; Paolo Latini; Mattia Frontini; Fabrizio Palitti; Jean-Marc Egly; Luca Proietti-De-Santis
Journal:  EMBO J       Date:  2008-09-11       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.